Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 117 от 222

Набира участници Фаза 2

Pembrolizumab in High-risk Thyroid Cancer

Differentiated Thyroid Cancer

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.

Начало: 20.12.2024 Край: 01.11.2026 Възраст: от 18 г.

Italy Istituti Clinici Scientifici Maugeri SpA NCT05852223

Набира участници Фаза 1

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IVB Prostate Cancer AJCC v8

This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other places is the body (metastatic). Bipolar androgen therapy is the regulation of testosterone between castration levels (lower than what would be normally present) and supraphysiological levels (amounts greater than normally found in the body). This may suppress cancer cell growth, which reduces prostate-specific antigen (PSA) levels and may delay cancer progression.

Начало: 19.12.2024 Край: 15.12.2027 Възраст: от 18 г.

United States Roswell Park Cancer Institute NCT06305598

Набира участници Фаза 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Focal Segmental Glomerulosclerosis Glomerulonephritis Minimal Lesion

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, brivekimig, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years. Study details for each participant include: The study duration will be up to 76 weeks. The treatment duration will be 24 weeks. There will be up to 18 visits.

Начало: 19.12.2024 Край: 16.02.2028 Възраст: 16–75 г. Лечение

Argentina, Australia, Brazil +18 Sanofi NCT06500702

Набира участници

Testimonials and Navigation in Rheumatology

Rheumatologic Disease Autoimmune Diseases

The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.

Начало: 18.12.2024 Край: 28.02.2028 Възраст: от 18 г.

United States University of Alabama at Birmingham NCT06469788

Набира участници Фаза 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Acute Myelogenous Leukemia Myelodysplastic Syndromes (MDS)

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Начало: 18.12.2024 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia, China, United States Beijing InnoCare Pharma Tech Co., Ltd. NCT06656494

Набира участници Фаза 1

A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

Diabetic Macular Edema Diabetic Retinopathy

THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.

Начало: 18.12.2024 Край: 28.02.2026 Възраст: 18–80 г. Лечение

Australia Therini Bio Pty Ltd NCT06701721

Набира участници Фаза 3

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Multifocal Motor Neuropathy (MMN) MMN

The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion

Начало: 18.12.2024 Край: 01.12.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +19 argenx NCT06742190

Набира участници Фаза 1

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

Spinocerebellar Ataxia Type 2

Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

Начало: 17.12.2024 Край: 01.12.2026 Възраст: 18–65 г. Лечение

Australia, Canada, France +5 Arrowhead Pharmaceuticals NCT06672445

Набира участници Фаза 2

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Graves' Disease

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

Начало: 17.12.2024 Край: 01.06.2028 Възраст: 18–75 г.

Belgium, Georgia, Germany +7 Immunovant Sciences GmbH NCT06727604

Набира участници Фаза 2/3

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

Начало: 17.12.2024 Край: 01.10.2031 Лечение

Australia, United Kingdom, United States Replimune, Inc. NCT06581406

Набира участници Фаза 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Multiple Myeloma Newly Diagnosed Multiple Myeloma

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

Начало: 16.12.2024 Край: 28.04.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 GlaxoSmithKline NCT06679101

Набира участници

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Ultomiris-exposed Pregnant/ Postpartum Pregnancy Paroxysmal Nocturnal Hemoglobinuria (PNH) Atypical Hemolytic Uremic Syndrome (aHUS) +2

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

Начало: 16.12.2024 Край: 11.07.2034

Australia, France, Germany +4 Alexion Pharmaceuticals, Inc. NCT06312644

Набира участници Фаза 1/2

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as first-line therapy in participants with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The study will begin with a safety lead-in phase (Phase 1b study) to determine the recommended combination dose (RDC) and then will transition to an expansion phase (Phase 2 study) to assess the clinical activity of ivosidenib in combination with durvalumab and gemcitabine/cisplatin at the RCD. During the treatment period participants will have study visits on days 1, 8, and 15 of Cycle 1, on days 1 and 8 of Cycle 2 to 8, and on day 1 of each additional cycle. Cycles 1 through 8 are 21 day cycles, and each following cycle is 28 days. Approximately 30 days and 90 days after treatment has ended, safety follow-up visits will occur and then participants will be followed for survival every 3 months. Study visits may include blood tests, ECG, vital signs, and a physical examination.

Начало: 16.12.2024 Край: 13.09.2027 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +6 Institut de Recherches Internationales Servier NCT06501625

Набира участници Фаза 1

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic Breast Cancer +2

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

Начало: 16.12.2024 Край: 30.08.2027 Възраст: от 18 г. Лечение

Australia, United States Olema Pharmaceuticals, Inc. NCT06784193

Набира участници Фаза 1

Study of BM230 in Patients With Advanced Solid Tumors

Solid Tumor

This study is a Phase I, multicenter, non-randomized, open-label, first-in-human study of BM230 conducted globally. The study will include two parts: a dose escalation part (Phase Ia) followed by a dose expansion part (Phase Ib). Phase Ia part will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors (HER2-related solid tumors). The Phase Ib part will enroll 5 distinct cohorts of patients with advanced solid tumors related to HER2 under MTD/RED doses, to better define the safety profile of BM230 and evaluate the efficacy of BM230.

Начало: 16.12.2024 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, China Suzhou Biomissile Pharmaceuticals Co., Ltd. NCT06644300

Набира участници

Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients

Obstetric Complication Gynecologic Cancer Lung Diseases Ultrasound

Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population

Начало: 15.12.2024 Край: 01.05.2026

Egypt Ain Shams University NCT06728709

Набира участници

Hybrid Effectiveness-Implementation Trial of an Executive Functioning Intervention for Children's Mental Health Services

Autism Spectrum Disorder Executive Functioning

This project aims to follow up on a prior project examining the impact of training therapists in an executive functioning intervention Unstuck and On Target (UOT) adapted for community mental health settings. Study aims are to test the clinical and implementation effectiveness of training mental health therapists in Unstuck and On Target, an executive functioning intervention, relative to Unified Protocol for Children, a transdiagnostic intervention for emotional disorders. This includes examining the implementation of Unstuck and associated outcomes (e.g., effective delivery, expanded use of Unstuck beyond autism, the feasibility of Unstuck) and impact on changes in child executive functioning and behaviors.

Начало: 15.12.2024 Край: 31.08.2029 Възраст: 6–99 г.

United States San Diego State University NCT06651086

Набира участници

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Pancreatic Carcinoma

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Начало: 12.12.2024 Край: 01.11.2029 Възраст: от 18 г.

United States Mayo Clinic NCT06271291

Набира участници Фаза 3

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Asthma

The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objectives are: * To evaluate the efficacy of Fp/ABS eMDPI administered four times daily * To evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeks * To investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single dose The planned study duration for each participant is approximately 10 weeks, excluding an optional prescreening visit.

Начало: 12.12.2024 Край: 31.05.2026 Възраст: от 12 г.

Argentina, Bulgaria, Czechia +9 Teva Branded Pharmaceutical Products R&D LLC NCT06664619

Набира участници

A Prospective, Multicenter, Open-label Study of the Beacon Platform for Holmium Laser Enucleation of the Prostate (HoLEP)

Benign Prostatic Hyperplasia

Robotic assisted surgery for benign prostatic hyperplasia (BPH)

Начало: 12.12.2024 Край: 30.12.2026 Възраст: от 45 г. Лечение

Chile, New Zealand Andromeda Surgical NCT06668142

1 … 115 116 117 118 119 … 222